A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma (DREAMM-9)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: SVHM HREC 228/20
NMA SSA Reference Number: SSA/68996/MonH-2021-251023(v2)
Monash Health Reference: RES-21-0000-007X
Effective start/end date1/02/2131/01/26


  • clinical trial
  • treatment efficacy
  • treatment safety
  • Myeloma